This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gurova, K. V. Articles by Gudkov, A. V. Search for Related Content PubMed PubMed Citation Articles by Gurova, K. V. Articles by Gudkov, A. V.

Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells¹

Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195 [K. V. G., A. V. B., L. G. B., P. M. C., A. V. G.], and Department of Pathology, University of Iowa, Iowa City, Iowa 52242 [O. W. R., M. B. C.]

Both inactivation of p53 function and loss of sensitivity to Fas contribute to a malignant phenotype and frequently occur during tumor progression. Although in the majority of cases only one of the p53 alleles is mutated, some tumors acquire mutations in both alleles of the p53 gene. To determine the biological significance of this phenomenon, we analyzed p53 mutants, p53^223Leu and p53^274Phe, from Fas-resistant prostate carcinoma cell line DU145. Both mutants differed from wild-type p53 in their conformation, transactivation ability, and effect on the growth of p53-deficient cells, with p53^223Leu being more similar to wild-type p53 than was p53^274Phe. Interestingly, the biological effect of coexpression of the DU145-derived mutants was dramatically different from that of each mutant expressed alone. Whereas neither of the two mutants was found to be dominant-negative against wild-type p53, each neutralized the other’s growth-suppressive effects and, in combination, were capable of down-regulating Fas expression and converting Fas-sensitive prostate carcinoma cells PC3 into Fas-resistant ones. These results indicate that two different p53 mutants that are separately rather weak can cooperate to generate p53 protein with anti-Fas function that is likely to provide additional selective advantages to the tumor.

This article has been cited by other articles:

				Z. Fabian, C. M. Csatary, J. Szeberenyi, and L. K. Csatary p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell Lines J. Virol., March 15, 2007; 81(6): 2817 - 2830. [Abstract] [Full Text] [PDF]

				C. W. Tam, A. S. Cheng, R. Y. M. Ma, K.-M. Yao, and S. Y. W. Shiu Inhibition of Prostate Cancer Cell Growth by Human Secreted PDZ Domain-Containing Protein 2, a Potential Autocrine Prostate Tumor Suppressor Endocrinology, November 1, 2006; 147(11): 5023 - 5033. [Abstract] [Full Text] [PDF]

				C. Lee, B. A. Smith, K. Bandyopadhyay, and R. A. Gjerset DNA Damage Disrupts the p14ARF-B23(Nucleophosmin) Interaction and Triggers a Transient Subnuclear Redistribution of p14ARF Cancer Res., November 1, 2005; 65(21): 9834 - 9842. [Abstract] [Full Text] [PDF]

				U. McDermott, D. B. Longley, L. Galligan, W. Allen, T. Wilson, and P. G. Johnston Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer Cancer Res., October 1, 2005; 65(19): 8951 - 8960. [Abstract] [Full Text] [PDF]